FAKTION: Updated and Expanded Analysis of Fulvestrant + Capivasertib or Placebo After Aromatase Inhibitor Therapy in ER+/HER2- Advanced Breast Cancer

June 3-7, 2022; Chicago, Illinois
Results from the randomized phase II FAKTION trial showed that the addition of capivasertib to fulvestrant prolongs survival in ER+/HER2- advanced breast cancer and suggest that capivasertib primarily benefits patients with PI3K/AKT/PTEN pathway alterations.
Format: Microsoft PowerPoint (.ppt)
File Size: 189 KB
Released: June 9, 2022


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Seagen & Genmab

Related Content

Video featuring global experts discussing the latest advances in HER2-low advanced breast cancer, including managing the use and safety of antibody–drug conjugates, from Clinical Care Options (CCO)

person default Nadia Harbeck, MD, PhD Komal Jhaveri, MD Heather McArthur, MD, MPH Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 19, 2023 Expired: January 18, 2024

Downloadable slideset on key points from a podcast on how to optimize personalized care of patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: January 18, 2023

On-demand Clinical Care Options (CCO) webcast: experts discuss how to optimize the personalized care of patients with TNBC

Mark Pegram, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME credit Released: January 12, 2023 Expired: January 11, 2024

Downloadable slides on multidisciplinary approaches to managing high-risk, HR-positive/HER2-negative early breast cancer, from Clinical Care Options, (CCO)

Erika P. Hamilton, MD
Program Director
Joyce O'Shaughnessy, MD
Program Director
Released: January 4, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings